Ward WH
,
Meeker CR
,
Handorf E
,
Hill MV
,
Einarson M
,
Alpaugh RK
,
Holden TL
,
Astsaturov I
,
Denlinger CS
,
Hall MJ
,
Reddy SS
,
Sigurdson ER
,
Dotan E
,
Zibelman M
,
Meyer JE
,
Farma JM
,
Vijayvergia N
Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal Cancer
JCO Clin Cancer Inform. 2021 Jan;5
:125-133
PMID:
33492994
URL:
https://www.ncbi.nlm.nih.gov/pubmed/33492994
Abstract
PURPOSE: Performance status (PS) is a subjective assessment of patients' overall health. Quantification of physical activity using a wearable tracker (Fitbit Charge [FC]) may provide an objective measure of patient's overall PS and treatment tolerance. MATERIALS AND METHODS: Patients with colorectal cancer were prospectively enrolled into two cohorts (medical and surgical) and asked to wear FC for 4 days at baseline (start of new chemotherapy [± 4 weeks] or prior to curative resection) and follow-up (4 weeks [± 2 weeks] after initial assessment in medical and postoperative discharge in surgical cohort). Primary end point was feasibility, defined as 75% of patients wearing FC for at least 12 hours/d, 3 of 4 assigned days. Mean steps per day (SPD) were correlated with toxicities of interest (postoperative complication or ≥ grade 3 toxicity). A cutoff of 5,000 SPD was selected to compare outcomes. RESULTS: Eighty patients were accrued over 3 years with 55% males and a median age of 59.5 years. Feasibility end point was met with 68 patients (85%) wearing FC more than predefined duration and majority (91%) finding its use acceptable. The mean SPD count for patients with PS 0 was 6,313, and for those with PS 1, it was 2,925 (122 and 54 active minutes, respectively) (P = .0003). Occurrence of toxicity of interest was lower among patients with SPD > 5,000 (7 of 33, 21%) compared with those with SPD < 5,000 (14 of 43, 32%), although not significant (P = .31). CONCLUSION: Assessment of physical activity with FC is feasible in patients with colorectal cancer and well-accepted. SPD may serve as an adjunct to PS assessment and a possible tool to help predict toxicities, regardless of type of therapy. Future studies incorporating FC can standardize patient assessment and help identify vulnerable population.
Notes
2473-4276
Ward, William H
Meeker, Caitlin R
Handorf, Elizabeth
Hill, Maureen V
Einarson, Margret
Alpaugh, R Katherine
Holden, Thomas L
Astsaturov, Igor
Denlinger, Crystal S
Hall, Michael J
Reddy, Sanjay S
Sigurdson, Elin R
Dotan, Efrat
Zibelman, Matthew
Meyer, Joshua E
Farma, Jeffrey M
Vijayvergia, Namrata
Journal Article
United States
JCO Clin Cancer Inform. 2021 Jan;5:125-133. doi: 10.1200/CCI.20.00117.
|